Answers are grounded in this paper and cite their sources.
Real-life study shows improved anatomical outcomes in eyes with nAMD nonresponse to Aflibercept, suggesting effective treatment.
Switching to faricimab may offer a valuable therapeutic option for recalcitrant nAMD, particularly in eyes with persistent SRF, providing improved anatomical outcomes while maintaining visual acuity in real-life practice. Prospective studies are warranted to better define response profiles and guide personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Bernal-Morales et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: